Head to Head Survey: MariMed (MRMD) and The Competition

MariMed (OTCMKTS:MRMDGet Rating) is one of 49 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it contrast to its peers? We will compare MariMed to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, valuation and dividends.

Analyst Ratings

This is a summary of recent recommendations for MariMed and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MariMed 0 0 2 0 3.00
MariMed Competitors 284 690 688 31 2.28

MariMed currently has a consensus price target of $2.25, suggesting a potential upside of 265.85%. As a group, “Medicinals & botanicals” companies have a potential upside of 123.32%. Given MariMed’s stronger consensus rating and higher probable upside, analysts clearly believe MariMed is more favorable than its peers.

Insider and Institutional Ownership

0.3% of MariMed shares are owned by institutional investors. Comparatively, 16.3% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 20.0% of MariMed shares are owned by company insiders. Comparatively, 26.3% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


This table compares MariMed and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MariMed 5.70% 20.87% 6.07%
MariMed Competitors -162.11% -157.55% -3.53%

Risk and Volatility

MariMed has a beta of 3.27, indicating that its stock price is 227% more volatile than the S&P 500. Comparatively, MariMed’s peers have a beta of 1.49, indicating that their average stock price is 49% more volatile than the S&P 500.

Earnings & Valuation

This table compares MariMed and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MariMed $121.46 million $7.22 million 30.77
MariMed Competitors $238.87 million -$88.85 million -7.48

MariMed’s peers have higher revenue, but lower earnings than MariMed. MariMed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


MariMed beats its peers on 9 of the 13 factors compared.

MariMed Company Profile (Get Rating)

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.